StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

ProQR Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -233.4%. For fiscal 2025 it was -273.1%, against -161.2% the year before. The highest annual figure on record is -161.2% in fiscal 2024.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-273.1%−112.0
FY2024Dec 31, 2024-161.2%+327.9
FY2023Dec 31, 2023-489.1%+1323.9
FY2022Dec 31, 2022-1813.0%+2472.4
FY2021Dec 31, 2021-4285.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-100.7%+220.2
Q1 FY2026Mar 31, 2026-671.4%−432.0
Q4 FY2025Dec 31, 2025-194.0%+40.0
Q3 FY2025Sep 30, 2025-391.5%−164.7
Q2 FY2025Jun 30, 2025-320.9%−263.8
Q1 FY2025Mar 31, 2025-239.3%−57.9
Q4 FY2024Dec 31, 2024-234.1%−43.2
Q3 FY2024Sep 30, 2024-226.8%+312.7
Q2 FY2024Jun 30, 2024-57.1%+674.1
Q1 FY2024Mar 31, 2024-181.5%+1252.0
Q4 FY2023Dec 31, 2023-190.9%+1539.7
Q3 FY2023Sep 30, 2023-539.5%+1895.8
Q2 FY2023Jun 30, 2023-731.2%+971.2
Q1 FY2023Mar 31, 2023-1433.4%+74.9
Q4 FY2022Dec 31, 2022-1730.6%+5519.7
Q3 FY2022Sep 30, 2022-2435.3%−765.9
Q2 FY2022Jun 30, 2022-1702.4%+3731.0
Q1 FY2022Mar 31, 2022-1508.3%–
Q4 FY2021Dec 31, 2021-7250.2%–
Q3 FY2021Sep 30, 2021-1669.4%–
Q2 FY2021Jun 30, 2021-5433.3%–

More ProQR Therapeutics figures

See a number that looks wrong?